Trial Profile
A phase 1 randomized crossover study of Bictegravir/emtricitabine/tenofovir alafenamide low dose tablet relative to bioavailability in Healthy adult volunteers and pharmacokinetics in children with HIV
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2020
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 06 Apr 2020 New trial record
- 11 Mar 2020 Results of phase 1 study and phase 2/3 study: NCT02881320 (n=12) were presented at the 27th Conference on Retroviruses and Opportunistic Infections